Log in

CVE:ZOMZomedica Pharmaceuticals Stock Price, Forecast & News

C$0.28
0.00 (0.00 %)
(As of 02/10/2020)
Add
Compare
Today's Range
C$0.29
Now: C$0.29
C$0.29
50-Day Range
C$0.29
MA: C$0.29
C$0.29
52-Week Range
C$0.29
Now: C$0.29
C$0.56
VolumeN/A
Average Volume2,858 shs
Market CapitalizationC$36.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.64 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone734-369-2555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.01 per share
Book ValueC($0.08) per share

Profitability

Miscellaneous

Employees27
Market CapC$36.73 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for ZOM and its competitors with MarketBeat's FREE daily newsletter.

Zomedica Pharmaceuticals (CVE:ZOM) Frequently Asked Questions

Has Zomedica Pharmaceuticals been receiving favorable news coverage?

News coverage about ZOM stock has trended very negative on Thursday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zomedica Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Zomedica Pharmaceuticals.

Who are some of Zomedica Pharmaceuticals' key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals investors own include Heat Biologics (HTBX), Ritter Pharmaceuticals (RTTR), Titan Pharmaceuticals (TTNP), Vislink Technologies (VISL), Callon Petroleum (CPE), Guardion Health Sciences (GHSI), Plug Power (PLUG), Anavex Life Sciences (AVXL), Biocept (BIOC) and Correvio Pharma (CORV).

Who are Zomedica Pharmaceuticals' key executives?

Zomedica Pharmaceuticals' management team includes the following people:
  • Mr. Gerald L. Solensky Jr., Chairman, Pres & CEO (Age 45)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 52)
  • Dr. Stephanie Morley D.V.M., DVM, COO & VP of Product Devel. (Age 44)
  • Mr. Michael Schilk, VP of Sales
  • Mr. David Eaton, VP of Marketing

What is Zomedica Pharmaceuticals' stock symbol?

Zomedica Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."

How do I buy shares of Zomedica Pharmaceuticals?

Shares of ZOM and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Zomedica Pharmaceuticals' stock price today?

One share of ZOM stock can currently be purchased for approximately C$0.29.

How big of a company is Zomedica Pharmaceuticals?

Zomedica Pharmaceuticals has a market capitalization of C$36.73 million. Zomedica Pharmaceuticals employs 27 workers across the globe.

What is Zomedica Pharmaceuticals' official website?

The official website for Zomedica Pharmaceuticals is www.zomedica.com.

How can I contact Zomedica Pharmaceuticals?

The company can be reached via phone at 734-369-2555.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.